The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.
 
Toshiaki Iwase
No Relationships to Disclose
 
Angela Alexander
Research Funding - Carisma Therapeutics; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Merck; Preferred Medicine
 
Evan N. Cohen
No Relationships to Disclose
 
Hui Gao
No Relationships to Disclose
 
Vivian Y Chiv
No Relationships to Disclose
 
Megumi Kai
No Relationships to Disclose
 
Kumiko Kida
Speakers' Bureau - AstraZeneca; Chugai Pharma; Taiho Pharmaceutical
 
Savitri Krishnamurthy
Consulting or Advisory Role - AstraZeneca
Research Funding - Caliber ID; PathomIQ; Perimeter Medical
Patents, Royalties, Other Intellectual Property - Publication of text book from Elsevier
 
Dianne Liu
No Relationships to Disclose
 
Yu Shen
No Relationships to Disclose
 
David Luis Ramirez
No Relationships to Disclose
 
Alexandre Reuben
Honoraria - Adaptive Biotechnologies
Consulting or Advisory Role - Adaptive Biotechnologies
 
Debu Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Personalis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Daniel J. Booser
No Relationships to Disclose
 
Stacy L. Moulder
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Clinton Yam
Consulting or Advisory Role - Gilead Sciences
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Vicente Valero
No Relationships to Disclose
 
Bora Lim
Honoraria - Department of Defense; SABCS
Consulting or Advisory Role - AstraZeneca; Lilly; Natera; Novartis
Research Funding - Calithera Biosciences; Genentech; Merck; Puma Biotechnology; Takeda
 
James M. Reuben
No Relationships to Disclose
 
Naoto T. Ueno
Stock and Other Ownership Interests - Pear Bio
Honoraria - Amgen; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Henry Stewart Talks; Kyowa Hakko Kirin; Kyowa Kirin International; Novartis; Pfizer; Pfizer; Puma Biotechnology; Rakuten Medical; Sumitomo Dainippon Pharma Oncology; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Carna Biosciences; Daiichi Sankyo; Eisai; Immunomedics; Kechow Pharma; OncoCyte; Phoenix Molecular Designs; Preferred Medicine; Takeda
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; CytoDyn; Daiichi Sankyo; Duality Biologics; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex